GlassScriptPhysician profile
Clinton Emmitt Branch
NPI 1184739435
$7,836.19
in general payments reported to CMS, 2019-2025
34 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,634 · 2020: $745 · 2021: $132 · 2023: $148 · 2024: $63.69 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $5,391.89 | 2019-2023 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $906.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $119.99 | 2021 | |
| Emd Serono, INC. | $107.65 | 2019-2020 | |
| Eisai INC. | $101.65 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $89.75 | 2019-2020 | |
| Ucb, INC. | $85.27 | 2019-2023 | Briviact |
| Genzyme Corporation | $75.09 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $72.25 | 2019 | |
| Allergan, INC. | $69.58 | 2019 | |
| Avanir Pharmaceuticals, INC. | $66.41 | 2019 | |
| Upsher-Smith Laboratories LLC | $59.75 | 2019 | |
| Biogen, INC. | $59.45 | 2019-2025 | Tysabri, Vumerity |
| Kyowa Kirin, INC. | $52.38 | 2021-2024 | Nourianz |
| Abbvie INC. | $43.25 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42.33 | 2019-2023 | Ultomiris |
| Tanabe Pharma America, INC. | $42.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.60 | 2019 | |
| Csl Behring | $40.10 | 2019 | |
| Boston Scientific Corporation | $37.99 | 2019-2025 | General - Pain Management |
| Supernus Pharmaceuticals, INC. | $35.25 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $32.99 | 2023 | Relyvrio |
| Mdd US Operations, LLC | $32.07 | 2019 | |
| Ge Healthcare | $31.12 | 2019 | |
| Neurelis, INC. | $29.33 | 2024 | Valtoco |
| Argenx US, INC. | $27.73 | 2025 | |
| Sunovion Pharmaceuticals INC. | $22.79 | 2019 | |
| Neurocrine Biosciences, INC. | $22.08 | 2019 | |
| Amgen INC. | $19.55 | 2019 | |
| Grifols USA, LLC | $17.88 | 2023 | Gamunex-C |
| Merz North America, INC. | $17.58 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.05 | 2019 | |
| Impel Pharmaceuticals INC. | $14.41 | 2023 | Trudhesa |
| Lilly USA, LLC | $13.09 | 2024 | Kisunla, Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.